1. Introduction {#sec1}
===============

Stenting has become widely accepted as the treatment of unresectable distal malignant biliary obstructions (UDMBO), since Soehendra and Reynders-Frederix \[[@B1]\] first introduced transpapillary biliary drainage in 1980. However, the patency and incidence of adverse events (dysfunctions and complications) have an influence on the quality of life. Stent dysfunction comprised stent migration, stent occlusion causing tumor over- and/or ingrowth, which included proximal overgrowth, distal overgrowth, proximal and distal overgrowth, ingrowth, and encrustation (sludge) \[[@B2]\]. It can be confirmed by subsequent radiologic studies, including computed tomography, percutaneous cholangiography, and endoscopic retrograde cholangiopancreatography, and based on lab test such as recurrent jaundice. Complication comprised hemorrhage, cholecystitis, pancreatitis retroperitoneal, perforation, and cholangitis (medical therapy), which was suspected based on clinical symptoms and signs. There are various types of stents used for the management of UDMBO: plastic stents, self-expandable metallic stent (SEMS) such as uncovered and covered stents, and recent developed bioabsorbable or biodegradable stents \[[@B3]\]. SEMS is considered to be the most cost-effective biliary stent for treatment of unresectable malignant biliary obstructions (UDMBO), but there is still some debate on the selection of covered or uncovered SEMS in distal duct strictures. The main disadvantage of covered SEMS is migration, because of nonembedded stent body, while the uncovered SEMSs which were embedded into the biliary wall are resistant to migration, because of their mesh structure and self-expandability. Unluckily, the tumor ingrowth (TI) via the stent mesh is the main cause of occlusion in uncovered SEMS. Although there are some randomized studies comparing covered and uncovered SEMS, the results are different according to each study. One \[[@B4]\] showed that covered SEMS had longer patency than uncovered SEMS; another \[[@B2], [@B5]\] revealed no statistically significant difference. Interestingly, the latest meta-analysis revealed that covered SEMS did not appear to have longer patency, and benefits brought by the two SEMSs to patients were not clear \[[@B6]\]. Unfortunately, the meta-analysis studies which focused on complications did not pay attention to the difference in patient survival and incidence of adverse event and dysfunction events. Therefore, it is essentially necessary to get a comprehensive understanding on the difference between uncovered and covered SEMS for the treatment of unresectable distal malignant biliary obstructions, especially stent patency, patient survival, and incidence of adverse events.

2. Materials and Methods {#sec2}
========================

This meta-analysis adhered to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

2.1. Study Selection {#sec2.1}
--------------------

The meta-analysis search was performed independently by two of the authors (Mr. Jiang and Mr. Yan), using MEDLINE, EMBASE, OVID, and Cochrane databases. The search was performed on all studies between 2010 and 2015 to compare covered and uncovered SEMS for unresectable distal malignant biliary obstructions. The search strategy was based on the following Medical Subject Heading terms (MeSH): "unresectable," "malignant biliary obstructions," "distal biliary obstructions," "distal biliary strictures," "covered," "uncovered," "self-expandable metallic stents," and "SEMS." Only studies on humans and in English and Chinese language were considered for inclusion. Reference lists of all retrieved articles were manually searched for additional studies.

2.2. Data Extraction and Conversion {#sec2.2}
-----------------------------------

Data extraction was performed independently by two reviewers (Mr. Jiang and Mr. Yan, resp.). The following parameters for each study included (1) first author, the year of publication, and the study type; (2) the number and characteristics of patients; (3) the outcome of the trials including number or incidence of adverse events (dysfunction and complication) and HR of elevated stent patency and patient survival, as well as their 95%. If available, the HRs with their 95% CIs and *P* values were collected from the original article or the corresponding E-mails. If not, we calculated HRs and their 95% confidence interval using the data of observed deaths, the data of samples in each group, or the data provided by the authors. If only Kaplan-Meier curves were available, we extracted data from the graphical survival plots and estimated the HRs. All the calculations mentioned above were based on the methods provided by Tierney et al. \[[@B7]\] and Parmar et al. \[[@B8]\].

2.3. Inclusion Criteria {#sec2.3}
-----------------------

The studies included in the meta-analysis had to fulfill the following criteria: (1) they should compare the original outcomes of covered and uncovered SEMSs for the treatment of unresectable distal malignant biliary obstructions; (2) they should report on at least stent patency, patient survival, and incidence of adverse events; (3) if dual (or multiple) studies were reported by the same institution and/or authors, only the most recent publication or the highest quality of studies was included.

2.4. Exclusion Criteria {#sec2.4}
-----------------------

The following studies were excluded: (1) those dealing with biliary malignant strictures or obstructions with second stents; (2) those using other types of stents, such as plastic stents; (3) those with no clearly reported outcomes; and (4) abstracts, letters, editorials and expert opinions, reviews without original data, case reports, and studies lacking control groups.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The meta-analysis was performed using Review Manager (RevMan), version 5.3. Stent patency and patient survival were analyzed using estimation of hazard ratios (HRs) with a 95% confidence interval (95% CI). Pooled effect was calculated using either the fixed or the random effects model. The test of heterogeneity of combined HRs was carried out using Cochran\'s *Q* test and Higgins *I*-squared statistic. If the *I* ^2^ statistic was \>50%, we considered heterogeneity to be present. If the probability of a chance occurrence was less than 5% (*P* \< 0.05), all statistical data were considered significant.

3. Results {#sec3}
==========

3.1. Selection of Trials {#sec3.1}
------------------------

After initial screening, of the 14 clinical trials \[[@B2], [@B5], [@B13]--[@B21], [@B9]--[@B20]\] which initially met the inclusion criteria, 2 \[[@B14], [@B20]\] did not display the specific comparison of the effects of covered and uncovered SEMS, 1 \[[@B9]\] used second stents, and 1 \[[@B5]\] dealt with patients who had received or were receiving chemotherapy, and 2 \[[@B18], [@B19]\] did not provide enough original data. Finally, 8 studies, including 2 retrospective studies and 6 prospective randomized studies, matched the selection criteria and were published between 2010 and 2015 ([Figure 1](#fig1){ref-type="fig"}). The characteristics of these 8 studies are summarized in [Table 1](#tab1){ref-type="table"}. The 8 studies included a total of 1067 patients: 524 in the covered SEMS group and 533 in the uncovered SEMS group. The sample size of each study varied from 30 to 191 patients. The proportion of men (OR = 1.02, 95% CI: 0.80--1.31, *P* = 0.85) and the proportion of pancreatic cancer in tumor etiology (OR = 0.97, 95% CI: 0.69--1.36, *P* = 0.87) were not significant.

3.2. Patient Survival {#sec3.2}
---------------------

All 8 studies reported patient survival. No statistical difference existed between the covered SEMS and uncovered SEMS in the hazard ratio of patient survival (HR 1.04; 95% CI, 0.92--1.17; *P* = 0.55). There is no heterogeneity among the 8 studies, and a fixed-effect model was used ([Figure 2](#fig2){ref-type="fig"}).

3.3. Stent Patency {#sec3.3}
------------------

As a fixed-effect model was used, the meta-analysis from the 8 studies also showed no significant difference of stent patency between two groups (HR 0.87, 95% CI: 0.58 to 1.30, *P* = 0.5) ([Figure 3](#fig3){ref-type="fig"}).

3.4. Complications and Dysfunctions Events {#sec3.4}
------------------------------------------

The statistical data was significantly favorable to covered SEMS group at incidence of adverse events (8 trials reported the data, OR: 0.74, 95% CI: 0.57 to 0.97, *P* = 0.03) ([Figure 4](#fig4){ref-type="fig"}), and there is a lower trend toward dysfunction events (8 trials reported the data, OR: 0.75, 95% CI: 0.56 to 1.00, *P* = 0.05) ([Figure 5](#fig5){ref-type="fig"}). However, there is no significant difference in complications (OR: 0.87, 95% CI: 0.58 to 1.30, *P* = 0.50) ([Figure 6](#fig6){ref-type="fig"}). According to the statistical data, the incidence of adverse events is lower in the covered SEMS, while there is no difference in complications.

3.5. Publication Bias {#sec3.5}
---------------------

The publication bias of included studies was evaluated by funnel plots. As is shown in [Figure 8](#fig8){ref-type="fig"}, the funnel plots were almost symmetric. Hence, there was no evidence for significant publication bias in our meta-analysis.

4. Discussion {#sec4}
=============

This meta-analysis shows that the covered SEMS group had lower incidence of adverse events (dysfunctions and complications) than the uncovered SEMS treatment group for unresectable distal malignant biliary obstructions. The main cause may be the higher reobstruction rates, which result from the tumor ingrowth and overgrowth after uncovered SEMS replacement. Although migration can contribute to the covered SEMS reobstruction or dysfunctions, the incidence may be lower than tumor ingrowth or overgrowth rate after uncovered SEMS replacement. Moreover, although the incidence of complications was not significantly different between covered and uncovered SEMS, a trend was shown in the rates of dysfunctions (OR: 0.75, 95% CI: 0.56 to 1.00, *P* = 0.05). This may explain better outcomes using covered SEMS.

Our results also suggest that covered SEMS should not provide a significant prolongation in cumulative stent patency when compared with uncovered SEMS. Although stent dysfunction had a trend towards being lower in covered SEMS at a given time, the stent patency was influenced by various factors, such as structural properties of SEMSs and presence of covering materials \[[@B23]\]. However, in the 8 trials, the follow-up end point was either last follow-up or patient death, and there was no difference in patient survival.

Acute pancreatitis and acute cholecystitis are the potential of complications, when the covered SEMS is placed over the cystic or pancreatic duct orifice. Although not proven in clinical studies, it has been claimed that covered SEMS might increase the prevalence of pancreatitis or cholecystitis by blocking the cystic duct orifice or pancreatic duct orifice. However, in our studies, we cannot come to the conclusion that the rate of complications was significant. It is probably due to the high portion of pancreatic cancer patients in the two groups. Additionally, this observation is commonly confounded by a low event rate \[[@B24]\]. What is more, such measures or precision may not be used widely in clinical practice in some hospitals. Therefore, it must be noted that measures were taken to reduce the rate of complications, either by using covered SEMSs with transmural drainage holes \[[@B12], [@B15]\] or by ensuring that the stent covering was placed below the level of the cystic or pancreatic duct.

In patients with unresectable malignant distal biliary obstruction, palliation may be offered with stent placement (either endoscopic or percutaneous). Endoscopic biliary stent placement seems to be associated with lower complication rate and better quality of life \[[@B25]\]. Therefore, endoscopic biliary stent placement is considered the gold standard, in order to improve success rates and patient outcomes. However, some studies \[[@B12], [@B15]\] we selected in this meta-analysis included percutaneous biliary stent placement, although ERCP was the initial approach, and PTC was performed when ERCP was not feasible. We cannot know how many participate in percutaneous biliary stent placement from the original article, but we get the same result in evaluating odds ratios of complications with endoscopic stent placement (OR: 0.94, 95% CI: 0.60 to 1.46, *P* = 0.39) ([Figure 7](#fig7){ref-type="fig"}).

4.1. Limitations and Strengths {#sec4.1}
------------------------------

Limitations of our analysis include the use of various covered SEMSs; ePTFE/FEP was used in two studies, whereas other materials (polyurethane, polycarbonate-polyurethane, and Permalume) were used in the remaining studies. Therefore, we assumed there were no differences in different types of covered SEMSs, like some published trials \[[@B4], [@B9], [@B26], [@B27]\].

The strength of this meta-analysis comes from the high methodological quality of each individual study as well as data homogeneity for most outcomes, including the primary outcome of stent patency, patient survival, and incidence of adverse events (dysfunctions and complications).

5. Conclusions {#sec5}
==============

Covered SEMS group had lower incidence of adverse events (dysfunctions and complications) than the uncovered SEMS group. There is no significant difference in dysfunctions, but covered SEMS trends to be better, and there is no difference in stent patency, patient survival, and complications. Compared with uncovered SEMS, covered SEMS is recommended for treating patients who are diagnosed as having unresectable distal malignant biliary obstructions.
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###### 

Baseline characteristics of studies included in the meta-analysis.

  Author/(yr)                       Type   Group    Covering material            Number      M/F         Mean age (yr)    Tumor etiology                                                 
  --------------------------------- ------ -------- ---------------------------- ----------- ----------- ---------------- ---------------- ----------- ---------- ---------- ----------- ---------
  Kullman et al. 2010 \[[@B2]\]     RCT    CSEMS    Polycarbonate-polyurethane   188         88/112      79.0 (39--100)   152 (76)         12 (6)      8 (4)      8 (3)      16 (8)      4 (2)
  UCSEMS                            191    91/109   76.0 (51--95)                155 (77)    10 (5)      9 (4)            3 (2)            18 (9)      5 (3)                             
  Gwon et al. 2010 \[[@B13]\]       NRCT   CSEMS    PTFE                         58          37/21       63.8 (35--84)    18 (31.0)        11 (19.0)   ---        6 (10.3)   19 (32.8)   4 (6.9)
  UCSEMS                            58     39/19    62.7 (24--86)                17 (29.3)   16 (27.6)   ---              5 (8.6)          19 (32.8)   1 (1.7)                           
  Krokidis et al. 2010 \[[@B12]\]   RCT    CSEMS    Viabil                       30          20/10       66.5 (52--78)    ---              30 (100)    ---        ---        ---         ---
  UCSEMS                            30     16/14    63.7 (46--73)                ---         30 (100)    ---              ---              ---         ---                               
  Krokidis et al. 2011 \[[@B15]\]   RCT    CSEMS    ePTFE/FEP                    40          17/23       65.0 ± 8.8       35 (87.5)        ---         ---        ---        ---         ---
  UCSEMS                            40     36/4     63.5 ± 9.8                   32 (80)     ---         ---              ---              ---         ---                               
  Li et al. 2012 \[[@B16]\]         NRCT   CSEMS    ePTFE                        35          20/15       64.4 ± 11.3      5 (14.3)         22 (62.9)   5 (14.3)   1 (5.9)    ---         2 (2.6)
  UCSEMS                            47     30/17    63.2 ± 11.5                  9 (19.1)    31 (65.9)   6 (12.8)         0 (0.0)          ---         1 (2.2)                           
  Kitano et al. 2013 \[[@B17]\]     RCT    CSEMS    Antimigration                60          25/35       70.6 ± 10.7      60 (100)         ---         ---        ---        ---         ---
  UCSEMS                            60     29/31    68.7 ± 8.9                   60 (100)    ---         ---              ---              ---                                           
  Ung et al. 2015 \[[@B22]\]        RCT    CSEMS    Hanaro                       34          18/16       77.0 (54--88)    30 (88)          ---         1 (3)      2 (6)      ---         2 (5.9)
  UCSEMS                            34     9/15     79.0 (54--92)                27 (79)     ---         3 (9)            5 (15)           ---         1 (2.9)                           
  Yang et al. 2015 \[[@B21]\]       RCT    CSEMS    Silicone                     51          34/17       68.7 ± 11.2      29 (56.9)        17 (33.3)   2 (3.9)    2 (3.9)    1 (2)       ---
  UCSEMS                            52     30/22    68.0 ± 11.3                  36 (69.2)   7 (13.5)    2 (3.8)          5 (9.6)          2 (3.8)     ---                               

RCT: randomized control trial; NRCT: nonrandomized control trial; CSEMS: covered self-expandable metallic stents; UCSEMS: uncovered self-expandable metallic stents; M: male; F: female.
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